Bristol Myers Squibb announced an R&D leadership shakeup that merges research responsibilities under Chief Medical Officer Cristian Massacesi, as Chief research officer Robert Plenge is set to depart in March. The internal restructuring aims to speed development and “capitalize on new technologies,” according to a company-described rationale cited in the reporting. The move signals how large pharma is reorganizing late-stage execution—particularly around translational throughput and decision-making speed—as pipeline pressure remains elevated. For competitors and dealmakers, leadership bundling can also affect how partnering and technology integration priorities are set across BMS.